Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2
Authors:
Open Access
- 9 December 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-14
Abstract
The scale and duration of neutralizing antibody responses targeting SARS-CoV-2 viral variants represents a critically important serological parameter that predicts protective immunity for COVID-19. In this study, we describe the development and employment of a new functional assay that measures neutralizing antibodies for SARS-CoV-2 and present longitudinal data illustrating the impact of age, sex and comorbidities on the kinetics and strength of vaccine-induced antibody responses for key variants in an Asian volunteer cohort. We also present an accurate quantitation of serological responses for SARS-CoV-2 that exploits a unique set of in-house, recombinant human monoclonal antibodies targeting the viral Spike and nucleocapsid proteins and demonstrate a reduction in neutralizing antibody titres across all groups 6 months post-vaccination. We also observe a marked reduction in the serological binding activity and neutralizing responses targeting recently newly emerged Omicron variants including XBB 1.5 and highlight a significant increase in cross-protective neutralizing antibody responses following a third dose (boost) of vaccine. These data illustrate how key virological factors such as immune escape mutations combined with host demographic factors such as age and sex of the vaccinated individual influence the strength and duration of cross-protective serological immunity for COVID-19.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- A 49-Year-Old Male With Fever and Abdominal PainClinical Infectious Diseases, 2021
- Vaccine Breakthrough Infections with SARS-CoV-2 VariantsNew England Journal of Medicine, 2021
- Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccineDiabetes/Metabolism Research and Reviews, 2021
- Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 studyNature Medicine, 2021
- SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targetseLife, 2021
- Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell FatesCell, 2020
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerabilityScience, 2020
- Sequencing and cloning of antigen-specific antibodies from mouse memory B cellsNature Protocols, 2016
- Hybridoma Technology for the Generation of Rodent mAbs via Classical Fusion2014
- The extent of affinity maturation differs between the memory and antibody‐forming cell compartments in the primary immune responseThe EMBO Journal, 1997